JP2025525990A - 感音難聴の治療のためのｂｄｎｆの鼻腔内投与 - Google Patents

感音難聴の治療のためのｂｄｎｆの鼻腔内投与

Info

Publication number
JP2025525990A
JP2025525990A JP2025507001A JP2025507001A JP2025525990A JP 2025525990 A JP2025525990 A JP 2025525990A JP 2025507001 A JP2025507001 A JP 2025507001A JP 2025507001 A JP2025507001 A JP 2025507001A JP 2025525990 A JP2025525990 A JP 2025525990A
Authority
JP
Japan
Prior art keywords
bdnf
hearing loss
treatment
concentration
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025507001A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025525990A5 (https=
Inventor
フェトーニ，アンナ・リタ
アラミニ，アンドレア
ブランドリーニ，ローラ
コッチアロ，パスクァーレ
ロメオ，ティツィアーナ
デッタ，ニコラ
アッパレンテ，ルチア
マッティオリ，シモーネ
カッターニ，フランカ
マンテルリ，フラビオ
アレグレッティ，マルチェッロ
Original Assignee
ドムペ・ファルマチェウティチ・ソチエタ・ペル・アツィオーニ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ドムペ・ファルマチェウティチ・ソチエタ・ペル・アツィオーニ filed Critical ドムペ・ファルマチェウティチ・ソチエタ・ペル・アツィオーニ
Publication of JP2025525990A publication Critical patent/JP2025525990A/ja
Publication of JP2025525990A5 publication Critical patent/JP2025525990A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2025507001A 2022-08-05 2023-08-04 感音難聴の治療のためのｂｄｎｆの鼻腔内投与 Pending JP2025525990A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22189067.6 2022-08-05
EP22189067.6A EP4316462A1 (en) 2022-08-05 2022-08-05 Intranasal administration of bdnf for the treatment of sensorineural hearing loss
PCT/EP2023/071676 WO2024028483A1 (en) 2022-08-05 2023-08-04 Intranasal administration of bdnf for the treatment of sensorineural hearing loss

Publications (2)

Publication Number Publication Date
JP2025525990A true JP2025525990A (ja) 2025-08-07
JP2025525990A5 JP2025525990A5 (https=) 2026-05-07

Family

ID=83080998

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025507001A Pending JP2025525990A (ja) 2022-08-05 2023-08-04 感音難聴の治療のためのｂｄｎｆの鼻腔内投与

Country Status (8)

Country Link
US (1) US20260048006A1 (https=)
EP (2) EP4316462A1 (https=)
JP (1) JP2025525990A (https=)
CN (1) CN119816318A (https=)
AU (1) AU2023317860A1 (https=)
CA (1) CA3263977A1 (https=)
IL (1) IL318653A (https=)
WO (1) WO2024028483A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4623926A1 (en) * 2024-03-26 2025-10-01 Dompe' Farmaceutici SpA Intranasal administration of bdnf for treatment of primary headaches

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2278999B1 (en) * 2008-04-21 2025-01-29 Dompé farmaceutici S.p.A. Auris formulations for treating otic diseases and conditions
WO2019140012A1 (en) * 2018-01-09 2019-07-18 Otonomy, Inc. Growth factor otic formulations
WO2021030452A1 (en) * 2019-08-14 2021-02-18 Decibel Therapeutics, Inc. Permeation enhancers, compositions containing them, and methods of using the same
WO2021151013A1 (en) * 2020-01-24 2021-07-29 Otonomy, Inc. Growth factor formulation for condition associated with otic event
US20240066099A1 (en) * 2020-12-15 2024-02-29 Dompé Farmaceutici S.P.A. Bdnf otic formulations and use thereof

Also Published As

Publication number Publication date
WO2024028483A1 (en) 2024-02-08
EP4565254A1 (en) 2025-06-11
US20260048006A1 (en) 2026-02-19
AU2023317860A1 (en) 2025-02-13
EP4316462A1 (en) 2024-02-07
CN119816318A (zh) 2025-04-11
CA3263977A1 (en) 2024-02-08
IL318653A (en) 2025-03-01

Similar Documents

Publication Publication Date Title
AU2005229543B2 (en) Use of an NMDA receptor antagonist for the treatment of tinnitus induced by cochlear excitotoxicity
US20100254907A1 (en) Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US10966940B2 (en) Methods for the treatment of tinnitus induced by cochlear excitotoxicity
JP2025525990A (ja) 感音難聴の治療のためのｂｄｎｆの鼻腔内投与
JP2025525989A (ja) 感音性難聴の治療のためのｎｇｆの鼻腔内投与
Kalkandelen et al. Comparative cochlear toxicities of streptomycin, gentamicin, amikacin and netilmicin in guinea-pigs
RU2789513C1 (ru) Интерферонсодержащая композиция для лечения хронических заболеваний верхних дыхательных путей
US11116719B2 (en) Methods of treating Meniere's disease
AU2019208152B2 (en) Treatment method
US20060233755A1 (en) Drug for auditory dysfunction
Plaza et al. Future Perspectives in Idiopathic Sudden Sensorineural Hearing Loss
JP2019513780A (ja) 耳疾患の処置における使用のための（＋）−アザセトロン
Rupasinghe Comparison-effectiveness of oral steroid versus intratympanic Dexamethasone for sudden onset sensorineural hearing loss
Edmunds Potential complications associated with steroid use in the middle and inner ear
RU2479328C2 (ru) Способ лечения поражений зрительного пути у пациентов с рассеянным склерозом
Azrin et al. Intratympanic Steroids Injection in Bilateral Sudden Sensorineural Hearing Loss
WO2019092770A1 (ja) 網膜疾患治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260423

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260423